首页 › 基金 › 683 Capital Management, LLC › PTGX
683 Capital Management, LLC 对 PTGX 的持仓历史
PROTAGONIST THERAPEUTICS INC · 医疗保健
683 Capital Management, LLC 在 Q3 2026 的 13F 申报中披露持有 PTGX(PROTAGONIST THERAPEUTICS INC)255,000 股,市值约 US$35.9M,约占其申报组合的 1.59%,在其申报持仓中市值排名第 14 位。 683 Capital Management, LLC 最近 13 个申报季度中有 13 个季度披露了 PTGX 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
683 Capital Management, LLC 对 PTGX 的持仓演变
683 Capital Management, LLC 于 Q3 2023 首次披露 PTGX 持仓:732,784 股(约 US$12.2M)。 该持仓在 Q3 2026 达到峰值 255,000 股,市值约 US$35.9M。 在 13 次申报中,683 Capital Management, LLC 2 次增持、10 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 255,000 股、市值约 US$35.9M,环比减持 -35,000 股。。 持仓曾出现大幅变动:Q4 2025 减持约 88% (随后一个季度股价上涨 21%)、Q1 2026 减持约 70% (随后一个季度股价上涨 16%)、Q2 2026 增持约 1821% (随后一个季度股价上涨 15%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 732.78K | $12.22M | 新进 |
| Q4 2023 | 715.00K | $16.39M | 减持 |
| Q1 2024 | 700.00K | $20.25M | 减持 |
| Q2 2024 | 604.45K | $20.94M | 减持 |
| Q3 2024 | 420.00K | $18.90M | 减持 |
| Q4 2024 | 410.00K | $15.83M | 减持 |
| Q1 2025 | 500.00K | $24.18M | 增持 |
| Q2 2025 | 445.00K | $24.60M | 减持 |
| Q3 2025 | 407.50K | $27.07M | 减持 |
| Q4 2025 | 50.30K | $4.39M | 减持 |
| Q1 2026 | 15.10K | $1.59M | 减持 |
| Q2 2026 | 290.00K | $35.55M | 增持 |
| Q3 2026 | 255.00K | $35.93M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 PTGX 与 13F 数据
PTGX(PROTAGONIST THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 48 只申报持有 PTGX,申报仓位最大的包括:FARALLON CAPITAL MANAGEMENT, L.L.C. (US$907.0M), 法拉龙资本管理 (US$778.2M), RTW INVESTMENTS, LP (US$713.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 PTGX 的基金
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.44M 股 · $907.04M · Q3 2026
- 法拉龙资本管理 6.35M 股 · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M 股 · $713.07M · Q3 2026
- JOHNSON & JOHNSON 2.45M 股 · $345.07M · Q3 2026
- Woodline Partners LP 1.41M 股 · $198.59M · Q3 2026
- ADAR1 Capital Management, LLC 951.40K 股 · $134.04M · Q3 2026
- Hood River Capital Management LLC 893.48K 股 · $125.88M · Q3 2026
- PERCEPTIVE ADVISORS LLC 981.88K 股 · $120.36M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 676.82K 股 · $95.36M · Q3 2026
- Eagle Health Investments LP 248.32K 股 · $34.99M · Q3 2026
更多关于 683 Capital Management, LLC
常见问题
How long has 683 Capital Management, LLC held PTGX?
683 Capital Management, LLC has disclosed PTGX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is 683 Capital Management, LLC's current position in PTGX?
As of Q3 2026, 683 Capital Management, LLC holds 255.00K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $35.93M, representing 1.59% of its reported portfolio and ranking #14.
Has 683 Capital Management, LLC been buying or selling PTGX?
In the latest 13F filing (Q3 2026), 683 Capital Management, LLC reduced its position in PTGX. The position peaked in Q3 2026 at 255.00K shares.
Which other funds hold PTGX?
Other major institutional holders of PTGX include FARALLON CAPITAL MANAGEMENT, L.L.C., 法拉龙资本管理, RTW INVESTMENTS, LP, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.